USRM (US Stem Cell) Total Liabilities: $14.81 Mil (As of Dec. 2022)


USRM US Stem Cell Inc USRM
12 GF Score
Price $0.00
View Full Analysis

What is US Stem Cell Total Liabilities?

US Stem Cell USRM -99.00% 12 Total Liabilities is $14.81 Mil as of Dec. 2022. GuruFocus rates USRM with a GF Score™ of 12/100.

US Stem Cell's Total Liabilities for the quarter that ended in Dec. 2022 was $14.81 Mil.

US Stem Cell's quarterly Total Liabilities increased from Jun. 2022 ($13.93 Mil) to Sep. 2022 ($14.37 Mil) and increased from Sep. 2022 ($14.37 Mil) to Dec. 2022 ($14.81 Mil).

US Stem Cell's annual Total Liabilities increased from Dec. 2020 ($11.67 Mil) to Dec. 2021 ($12.82 Mil) and increased from Dec. 2021 ($12.82 Mil) to Dec. 2022 ($14.81 Mil).

US Stem Cell Total Liabilities Historical Data

* Premium members only.

The historical data trend for US Stem Cell's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

US Stem Cell Total Liabilities Chart

US Stem Cell Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.70 9.57 11.67 12.82 14.81

US Stem Cell Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.82 13.51 13.93 14.37 14.81
USRM
12GF Score
US Stem Cell Inc USRM
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

US Stem Cell Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

US Stem Cell's Total Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.078+(0.682+-0.00099999999999884
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.054+0+0)
=14.81

Total Liabilities=Total Assets (A: Dec. 2022 )-Total Equity (A: Dec. 2022 )
=0.068--14.745
=14.81

US Stem Cell's Total Liabilities for the quarter that ended in Dec. 2022 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=14.078+(0.682+-0.00099999999999884
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0.054+0+0)
=14.81

Total Liabilities=Total Assets (Q: Dec. 2022 )-Total Equity (Q: Dec. 2022 )
=0.068--14.745
=14.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $14.81 Mil mean?
US Stem Cell (USRM) has a Total Liabilities of $14.81 Mil as of Dec. 2022. The total amount of liabilities as recorded on a company's balance sheet. View historical data for US Stem Cell and its competitors.
Is US Stem Cell's Total Liabilities too high?
US Stem Cell's current Total Liabilities is $14.81 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Total Liabilities compare to NOVNQ and RGRX?
US Stem Cell's Total Liabilities of $14.81 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for US Stem Cell and its competitors. US Stem Cell's current Total Liabilities is $14.81 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Total Liabilities of $14.81 Mil. The current Total Liabilities is $14.81 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For US Stem Cell (USRM), the current Total Liabilities is $14.81 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

US Stem Cell Business Description

Address 1560 Sawgrass Corporate Parkway, 4th Floor, Sunrise, FL, USA, 33323
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score

Get the complete analysis for USRM

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price